Series date: 
01/05/2024 - 7:00am MST to 12/31/2024 - 8:00am MST

These courses are intended for internal hospital staff.

Activity Description:

This multidisciplinary tumor board brings together health care professionals from multiple specialties to provide a team approach to patient care through peer-to-peer discussion and collaboration. With the rapidly changing advances in the medical field, this is a forum that will provide clinical staff the opportunity to discuss and share new cutting-edge science, clinical, prognostic, biologic, radiologic, and treatment information for all who attend. This multidisciplinary discussion helps bridge gaps across the continuum of care in order to enhance the overall quality of patient-centered cancer care.

Target Audience: 

Anesthesiology, Diagnostic Radiology, Dermatology, Surgical Oncology, Medical Oncology, Plastic Surgeons, Internal Medicine, Family Medicine, Nurse Practitioners and Physician Assistants

Learning Objectives:

  • Utilize multidisciplinary approaches to diagnosis and staging of patients with cancer including the findings from imaging, biopsy and surgery, genetic and molecular studies.
  • Implement optimal treatment plans for the patients with cancer integrating surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy as needed.
  • Describe evidence and/or guideline-based approaches to therapy as well as available clinical trials.
  • Address the cultural, linguistic, ethnic, religious, and socio-economic barriers which may affect a given patient’s treatment.

Moderator:

Nitin Chandramouli, MD, FACP

Gaye Foster

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of HCA Healthcare Continental Division and HCA Healthcare Mountain Division. HCA Healthcare Continental Division is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose. 

Series location: 
St. Marks Hospital Virtual
Salt Lake City, UT
United States

Sessions

Session Date
St. Marks Hospital General Tumor Board 05/03/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 05/10/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 05/17/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 05/31/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 06/07/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 06/14/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 06/21/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 07/05/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 07/12/2024 - 7:00am to 8:00am MDT
St. Marks Hospital General Tumor Board 07/19/2024 - 7:00am to 8:00am MDT

Pages